Sun Pharmaceutical Industries Ltd: Business Overview and Financial Analysis

Sun Pharmaceutical Industries Limited is India's largest commercial pharmaceutical enterprise and the fourth-largest specialty generic pharmaceutical manufacturer globally. The company operates an expansive worldwide network that manufactures and distributes branded generics, complex generic formulations, active pharmaceutical ingredients (APIs), and consumer healthcare products. Moving progressively up the value chain, Sun Pharma has transformed into an innovation-driven global pharmaceutical player by expanding its proprietary innovative and specialty product pipeline across core therapeutic segments.

Sun Pharma Geographic Revenue Mix (FY2025-26)

Sun Pharmaceutical Industries’ global operations are geographically diversified across mature and high-growth markets, insulating revenue growth from regulatory changes in individual jurisdictions.

• India Formulations – 33.2% of consolidated sales
• United States Formulations – 29.0% of consolidated sales
• Emerging Markets Formulations – 19.0% of consolidated sales
• Rest of World (RoW) Formulations – 15.0% of consolidated sales
• API and Other External Revenue – 3.8% of consolidated sales

Sun Pharma’s geographic revenue structure displays limited country concentration risk, with international markets contributing 67.0% of overall corporate revenue during the full financial year.

Business Portfolio and Segment Breakdown (FY2025-26)

Sun Pharma manages a diversified business portfolio across proprietary innovative medicines, generic formulations, and active pharmaceutical ingredients.

• Global Innovative Medicines – US$ 1,420 million (20.7% of consolidated sales)
• India Formulations Total Value – Rs 1,92,904 crore (+14.0% YoY expansion)
• External Active Pharmaceutical Ingredients (APIs) – Rs 6,740 crore for the March quarter
• New Product Introductions – 37 new domestic formulation assets commercialised

The expansion of Sun Pharmaceutical Industries’ Innovative Medicines segment, formerly designated as the Specialty business, serves as a key long-term margin driver for the company.

Sun Pharma Key Operational KPIs and Global Footprint (FY2025-26)

Sun Pharmaceutical Industries leverages its global manufacturing presence and patent portfolio to maintain market share across domestic and international pharmaceutical markets.

• Domestic Market Share Rank – No. 1 position in the Indian pharmaceutical sector
• Domestic Prescriptions Leadership – Rank No. 1 across 11 major medical doctor specialties
• Total Domestic Market Share – 8.4% share of the Indian pharma market (up from 8.1% YoY)
• US Approved ANDA Backlog – 552 cumulative product formulations approved
• US Pending ANDA Approvals – 122 abbreviated new drug filings awaiting final regulatory review
• Tentative US FDA Approvals – 28 product filings granted tentative administrative clearance
• Global Export Footprint – Active distribution channels operating across 100+ sovereign countries
• Emerging Markets Infrastructure – Operations established within 80+ developing economic zones

Sun Pharma’s continued domestic market share expansion marks its highest organic gain since the Ranbaxy integration, supporting pipeline monetisation across Indian distribution channels.

Research and Development Infrastructure (FY2025-26)

Sun Pharma maintains a capital-intensive research framework designed to develop complex novel molecules and support clinical data validation.

• Full-Year Research and Development (R&D) Spend – Rs 35,540 crore (6.1% of total sales)
• Core R&D Allocation for Innovative Lines – 36.9% of total research capital allocations
• Global R&D Technology Centres – 6 dedicated institutional research facilities operationalised
• Worldwide Research Workforce – 2,700+ full-time scientists and pharma tech practitioners
• New Drug Applications (NDAs) Portfolio – 57 approved new drug filings managed in the US
• Pipeline Pending NDA Clearance – 13 innovative drug applications awaiting US FDA review

Sun Pharmaceutical Industries’ continued investment in innovative and specialty products supports long-term pipeline development amid price erosion affecting traditional generic products.

Sun Pharma Financial and Solvency Position (As of March 31, 2026)

Sun Pharma’s balance sheet reflects low leverage, substantial reserves, and strong credit ratings.

• Equity Reserves and Surplus – Rs 83,330.20 crore managed across corporate books
• Total Paid-Up Capital Baseline – Rs 239.90 crore (retaining 2,399.3 million outstanding shares)
• Full-Year Recommended Corporate Dividend – Rs 16.00 per equity share (including Rs 5.00 final dividend)
• Corporate Long-Term Credit Rating – CRISIL AAA with a Stable outlook reaffirmed

High net worth and a debt-free standalone balance sheet provide Sun Pharmaceutical Industries with financial flexibility to pursue expansion opportunities during high interest-rate environments.

Consolidated Financial Performance (FY2025-26)

Sun Pharma’s full-year audited financial performance demonstrates double-digit growth in consolidated revenue and operating profit, supported by its global business portfolio.

• Consolidated Gross Revenue – Rs 5,82,201 million (+11.9% YoY expansion)
• Consolidated Operating Profit (EBITDA) – Rs 1,77,314 million (+16.1% YoY expansion)
• Consolidated EBITDA Margin Profile – 30.3% for the full fiscal year
• Consolidated Net Profit After Tax (PAT) – Rs 1,14,794 million (+5.0% YoY increase)

Sun Pharmaceutical Industries’ revenue growth was supported by the expansion of the US innovative medicines business, which surpassed US$ 1 billion in standalone annualised revenue.

Sun Pharma Latest Quarterly Financial Performance (Q4 FY2025-26)

Sun Pharma’s final-quarter financial performance shows growth in consolidated revenue and profitability alongside weaker standalone financial performance.

• Consolidated Core Sales Realisations – Rs 1,45,598 million (+13.6% YoY growth)
• Consolidated Quarterly Net Profit (PAT) – Rs 27,140 million (+26.2% YoY growth)
• Consolidated Quarterly EBITDA Output – Rs 39,542 million (+6.4% YoY growth)
• Consolidated Quarterly EBITDA Margin – 27.1% for the March quarter
• Standalone Quarterly Net Profit Collapse – Rs 608.70 crore (-70.0% YoY reduction)
• Standalone Core Operational Revenue – Rs 4,887.27 crore (-31.0% YoY drop)

Consolidated profit growth was supported by domestic formulation sales, while Sun Pharmaceutical Industries’ standalone performance was affected by localised raw material procurement expenses.

Corporate Actions and Strategic Alliances (FY2025-26)

Sun Pharma’s strategic acquisitions and product expansions support the continued development of its international commercial portfolio.

• Organon Asset Acquisition – Completed a definitive structural agreement to buy specialised product pipelines from Organon.
• US Innovative Revenue Mix Shift – Specialty business contributed over 50% of total US sales volumes for the first time.
• UNLOXCYT Label Update Approval – US FDA authorised updated clinical labeling for cutaneous squamous cell carcinoma indications.
• ILUMYA Supplemental Application Acceptance – US FDA accepted a supplemental biologics license application for active psoriatic arthritis.
• Domestic Hyperkalaemia Partnership – Signed a co-marketing agreement with AstraZeneca Pharma India Limited to co-distribute hyperkalaemia assets.

The definitive structural acquisition of Organon portfolio segments speeds up the enterprise's transformation from a classic generic producer to an asset-heavy innovative pharma player.

Sun Pharma Management Commentary and Strategic Outlook (FY2025-26)

Sun Pharmaceutical Industries’ management strategy focuses on expanding its proprietary innovative medicines portfolio while integrating acquired global products.

• US Formulation Performance Runway – Management intends to prioritise high-margin innovative entities like cosibelimab over generic products facing persistent price erosion.
• Domestic Formulation Velocity Targets – Leadership aims to outpace broader market expansions through active multi-product introduction programs across urban clinics.
• Operating Expenses and Cost Pressures – The corporation anticipates short-term elevated logistics outlays due to shifting international maritime freight rules.
• Innovative Pipeline Funding Rules – R&D allocations are guided to remain stable at 6.0% to 7.0% of annual turnover, favoring Phase 3 metabolic trials.
• Organon Asset Integration Roadmaps – Management expects the Organon transaction to immediately improve ex-US distribution synergies during early FY2026-27.
• Generic Product Pricing Outlook – Price erosion across classic US generic channels is projected to moderate into single-digit compression bands.

Sun Pharma’s strategy remains focused on reinvesting cash flows from its core generics business to expand its global innovative medicines portfolio across developed markets.

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Citations

[1] Sun Pharmaceutical Industries Limited Board Meeting Outcome & Financial Results Disclosures submitted to BSE Limited and National Stock Exchange of India Limited (May 2026).
[2] Sun Pharmaceutical Industries Limited Press Release: Q4 and Full-Year Financial Results for the Financial Year Ended March 31, 2026.
[3] Annual Report and Notice of the 34th Annual General Meeting of Sun Pharmaceutical Industries Limited (FY2025-26).
[4] CRISIL Ratings Limited Instrument Evaluation and Credit Rating Assessment for Sun Pharmaceutical Industries Limited (May 2026).
[5] Ticker Finology Professional Corporate Database on Sun Pharmaceutical Industries Limited (SUNPHARMA).

Disclaimer
The information presented above on Sun Pharmaceutical Industries Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on the Finology Ticker Sun Pharmaceutical Industries Limited page before making any investment decision.